NCT00455000View on ClinicalTrials.gov

A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Alzheimer's Disease
Interventions
BIOLOGICAL

PF-04360365

Monoclonal antibody

DRUG

Placebo

Placebo

Trial Locations (12)

3081

Pfizer Investigational Site, Heidelberg West

6009

Pfizer Investigational Site, Nedlands

6160

Pfizer Investigational Site, Fremantle

N6A 4G5

Pfizer Investigational Site, London

N6C 5J1

Pfizer Investigational Site, London

M3B 2W7

Pfizer Investigational Site, Toronto

M4N 3M5

Pfizer Investigational Site, Toronto

M5V 2T3

Pfizer Investigational Site, Toronto

H1T 2M4

Pfizer Investigational Site, Montreal

141 86

Pfizer Investigational Site, Stockholm

SO16 6YD

Pfizer Investigational Site, Southampton

SO30 3JB

Pfizer Investigational Site, Southampton

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY